Brief Summary
This research is designed to determine if experimental treatment with PARP inhibitora type of targeted therapy that blocks the poly (ADP-ribose) polymerase (PARP) enzyme, which plays a role in DNA repair - this can stop cancer cells from repairing themselves, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advancedat a late stage, far along solid tumors.
Intervention / Treatment
- Drug: AZD5305
- Drug: Paclitaxel
- Drug: Carboplatin
- Drug: T- Dxd
- Drug: Dato-DXd
- Drug: Camizestrant
Inclusion Criteria:
- Age ≥ 18 at the time of screeningtesting for cancer or conditions that can lead to cancer before symptoms appear, also known as cancer screening
- Histological or cytological confirmation of advanced malignancy considered to be suitable for study treatment and meeting module specific eligibility criteria..
- Eastern Cooperative Oncologythe study, diagnosis and treatment of cancer Group Performance status (ECOG PS: 0-2)
- Life expectancy ≥ 12 weeks
- Progressive cancera disease where abnormal cells split without control and spread to other nearby body tissue and/or organs at the time of study entry
- Patients must have evaluable disease as defined in module-specific criteria for Part A and Part B
- Adequate organ and marrow function as defined by the protocol.
- For Part B expansion cohorts: Provision of formalin-fixed and paraffin embedded (FFPE) tumoura tissue mass that forms from groups of unhealthy cells specimena sample for investigating (e.g. blood, stools, urine, sputum etc.) is mandatory, where available, except if stated that it is optional in a specific Module.
For Part A:
– Patients may have received up to one prior line of therapy with a PARPi-based regimen (either as a treatment or as maintenance)
For Part B:
– Patients must not have received prior therapy with a PARPi-based regimen (either as a treatment or as maintenance).